Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Acute Lymphoblastic Leukemia in Remission: early-phase trial registry

3 of 6 indexed Acute Lymphoblastic Leukemia in Remission trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Acute Lymphoblastic Leukemia in Remission: 6 US clinical trials tracked, 3 recruiting.

Acute Lymphoblastic Leukemia in Remission is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition acute-lymphoblastic-leukemia-in-remission

OPEN 3 | RECR 50% | LATE 0 | EARLY 4 | RANK #2866 | SPON 2

Nearest open-share peer: Achalasia (50% recruiting · 8 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leuk (th…50%Acute Renal Failure16.7%
Open-enrollment share among volume-matched conditions near Acute Lymphoblastic Leukemia in Remission

Acute Lymphoblastic Leukemia in Remission lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Acute Lymphoblastic Leukemia in Remission on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Acute Lymphoblastic Leukemia in Remission is recruiting above its size-band peers.

    3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Acute Lymphoblastic Leukemia in Remission research.

    City of Hope Medical Center accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Acute Lymphoblastic Leukemia in Remission trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Acute Lymphoblastic Leukemia in Remission research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Named interventions

Most-linked intervention names on Acute Lymphoblastic Leukemia in Remission records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Biological
2 trials
Cyclophosphamide Drug
2 trials
Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) Device
1 trials
Allogeneic Natural Killer Cell Line NK-92 Biological
1 trials
Clofarabine Drug
1 trials
CliniMACS Device
1 trials
Bone Marrow Transplantation Procedure
1 trials
Peripheral Blood Stem Cell Transplantation Procedure
1 trials

US sites by state

Facility locations filed on Acute Lymphoblastic Leukemia in Remission trials. A trial with sites in several states counts in each.

Texas 3 trials
California 2 trials
Wisconsin 1 trials
Washington 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Acute Lymphoblastic Leukemia in Remission page

6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Acute Lymphoblastic Leukemia in Remission trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • City of Hope Medical Center sponsors the most Acute Lymphoblastic Leukemia in Remission trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Lymphoblastic Leukemia in Remission condition card totals 6 registered trials; most-linked intervention Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.